In a randomized , double-blind , placebo-controlled trial involving 84,496 adults 65 years of age or older , we evaluated the efficacy of 13-valent polysaccharide conjugate vaccine ( PCV13 ) in preventing first episodes of vaccine-type strains of pneumococcal community-acquired pneumonia , nonbacteremic and noninvasive pneumococcal community-acquired pneumonia , and invasive pneumococcal disease .